Background: Approximately 15% of misoprostol-induced-abortions may not be successful, leading to in utero exposure to the drug and to the induction of a series of defects including central nervous system, limb and visceral defects. A common proposal is that the drug causes disruption of the fetal vasculature leading to embryonic or fetal hypoxia.
Aim: To evaluate the teratogenicity of misoprostol using the rat post-implantation embryo culture.
Material And Methods: Rat embryos were collected at the beginning of organogenesis and cultured in rat serum containing misoprostol at concentrations of 200, 2,000 or 20,000 pg/ml. Functionality, morphology and morphometry parameters were evaluated.
Results: Misoprostol induced a dose-dependent embryotoxic effect causing a decrease in embryo viability and function (poor vascular development and survival) and morphometry (alterations in branchial arches, heart and cephalic portions of the neural tube, among others).
Conclusions: All the manifestations observed are indicative of the ability of misoprostol to directly induce developmental retardation and alterations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Objective: Early pregnancy loss is a common complication of pregnancy. Research has demonstrated the efficacy of Mifepristone pre-treatment followed by Misoprostol for the induction of an early pregnancy loss (EPL). North York General Hospital (NYGH) provides an all-in-one Early Pregnancy Assessment Clinic (EPAC) to streamline the care of women with an EPL.
View Article and Find Full Text PDFNew Data on Ulipristal Acetate and Misoprostol for Medication Abortion - A Step Forward?
NEJM Evid
January 2025
Advancing New Standards in Reproductive Health (ANSIRH), Bixby Center for Global Reproductive Health, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco (UCSF).
A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion.
NEJM Evid
January 2025
Gynuity Health Projects, New York.
Background: The current regimen for early medication abortion in many countries is mifepristone and misoprostol, but mifepristone is relatively expensive and limited in many regions. Ulipristal acetate, with a similar chemical profile, might be an alternative. This proof-of-concept study evaluated ulipristal acetate and misoprostol for medication abortion through 63 days of gestation.
View Article and Find Full Text PDFSeeking abortion medications online: experiences from a mystery client study in Colombia.
BMJ Open
January 2025
Fundación Oriéntame, Bogotá, Colombia.
Objectives: While Colombians gained broad legal access to abortion in 2022, people still lack knowledge about its availability and face variable quality of care at health facilities. This study sought to understand whether online sellers provide the instructions and medication dosages necessary for effective medication abortions.
Design: The study design involved mystery clients contacting sellers identified across websites and social media platforms (Facebook, Instagram, and TikTok) to purchase abortion pills.
A disproportionality analysis of FDA adverse event reporting system events for misoprostol.
Sci Rep
January 2025
Department of Reproduction, Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, China.
Misoprostol was originally used to treat gastric ulcers, and has been widely used in abortion, cervical maturation, induced labour and postpartum hemorrhage. But there are still many undetected adverse events (AEs). The purpose of this study was to provide a comprehensive overview of the safety of misoprostol.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!